News for La Jolla Pharmaceutical Company (LJPC)

Summary Innoviva Inc (INVA), a diversified holding company with a focus on royalties and healthcare investments, announced that its CEO, Pavel Raifeld, will par

Robust royalty portfolio with strong partnerships and innovative healthcare assets.Expansion into critical care and infectious disease markets through strategi

Innoviva, Inc. (NASDAQ: INVA) (”œInnoviva” or the ”œCompany”), a diversified holding company with a core royalties portfolio, a leading critical care and

Innoviva Specialty Therapeutics, Inc., (”œIST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution

**media[493017]**

Innoviva, Inc. (NASDAQ: INVA) (”œInnoviva” or the ”œCompany”), a diversified holding company with a core royalties portfolio, a leading critical care and

SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti-infective product, eravacycline (XERAVA®), was recently presented in Los Angeles, California at IDWeek 2024. Among the findings, two in vitro study results further demonstrated the broad and consistent antimicrobial activity of eravacycline.

Innoviva to Participate in the UBS Global Healthcare Conference

According to a report by Fortune Business Insights, the Vasopressin for Vasoplegic Shock Market size sector reached a market value of USD 890.9 Million in 2019. Future projections show a bright…

As per Fortune Business Insights’ report, the vasopressin for vasoplegic shock Market share sector attained a worth of USD 890.9 Million in 2019. Forecasts indicate a promising path ahead, foreseeing…

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO ® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Ba

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on...

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to...

According to DelveInsight's’ estimates, the sepsis market in 7MM is expected to show good positive growth, during the forecast period (2023–2032), mainly...

Innoviva, Inc. , a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer,... | September 8, 2022

Read Financial Analysis: Brookline Capital Acquisition (NASDAQ:BCAC) vs. La Jolla Pharmaceutical (NASDAQ:LJPC) at ETF Daily News

Read Analysts’ New Coverage for May 24th (AAMC, AAU, ACU, ADXS, ALDX, APLD, AUMN, AZN, CFTLF, CRBP) at ETF Daily News

Read Research Analysts’ Downgrades for May 19th (AAVMY, AMCX, BK, BRG, COLL, CRARY, CSX, DOC, ELY, FF) at ETF Daily News